An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

In a statement, J&J said that the trial – which looked at the combination of TAR-200 with J&J's experimental PD-1 inhibitor cetrelimab given systemically – was "a bold approach to disrupt the ...

The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% ...

Ninety patients will be randomized to daily erdafitinib monotherapy versus combination erdafitinib + cetrelimab. The co-primary study endpoints are pathologic complete response and downstaging.

XOMA Royalty Corporation's portfolio includes riskier assets, impacting its stability. Find out why XOMA stock’s high-risk ...

At ESMO 2024, Bayer will present key results from the Phase III ARANOTE trial on NUBEQA® (darolutamide) for metastatic hormone-sensitive prostate cancer and the PEACE-III study of XOFIGO® (radium-223) ...